Angiex
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 Cambridgepark Dr Fl 5, Cambridge, Ma...Phone Number
(617) 576-1753Website
www.angiex.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Angiex
Angiex is focused on developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) aimed at addressing the critical aspects of cancer lethality. Their innovative Nuclear Delivery Platform enables targeted delivery of chemotherapeutic agents to the nucleus of tumor cells, potentially revolutionizing treatments for solid tumors. The company's lead ND-ADC, AGX101, is set to enter clinical trials along with a pipeline of additional therapies currently in development. Angiex aims to provide safe and effective cancer therapies, aspiring to make cancer a non-lethal disease.Explore more
Angiex Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Angiex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Angiex has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Angiex launches new products
Funding: Get notified immidiatlly once Angiex has new funding data
Congratulate Masked Content for being promoted to Masked Content at Angiex
Angiex, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Angiex recently announced quarterly report
Check out if Angiex is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Angiex had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Angiex
Find 2 more new buyers
Compare Similar Companies to Angiex
Compare insights from companies similar to Angiex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Angiex is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Angiex is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Angiex.
Angiex financials insights
Gather financial insights about Angiex, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$2.9M
2025
Private Equity
$11M
Angiex Tech Stack
A closer look at the technologies used by Angiex
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Partnership
Partnership, Research & Development, Logistics / Supply Chain, Medical Research
New Hire
Executive Move
Angiex News & Media
Angiex Completes Financings Totaling $31 Million to Advance Phase 1 Dose Escalation of Nuclear-Delivered ADC AGX101 in Patients with Advanced Solid Tumors
Proceeds support ongoing all-comers Phase 1 trial of TM4SF1-directed Nuclear-Delivered ADC AGX101 Proceeds support ongoing all-comers Phase 1 trial of TM4SF1-directed Nuclear-Delivered ADC AGX101Abzena Supplies Clinical Trial Material for Angiex's Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC
SAN DIEGO, Aug. 8, 2024 /PRNewswire/ -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for their Phase 1 clinical trial of AGX101, a first-in-class TM4SF1-directed Antibody-Drug Conjugate...Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the Phase 1 clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers.Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Duvall brings valuable global biotech experience to the company as it advances into clinical stage CAMBRIDGE, Mass., June 22, 2022 /PRNewswire/ -- Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, has appointed Marty J. Duvall as chief...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Angiex
Sign Up For FreeTo access detailed company insights
Angiex is focused on developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) aimed at addressing the critical aspects of cancer lethality. Their innovative Nuclear Delivery Platform enables targeted delivery of chemotherapeutic agents to the nucleus of tumor cells, potentially revolutionizing treatments for solid tumors. The... Read More
